Price
No data yet.
Social Signal Score
Analyst Ratings
58 analystsRevenue
$7.80B+4.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel O'Day
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 17,000
- Beta
- 0.35
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.57
Financials
Revenue
$7.80B+4.0%Net Income
$-10.50B-415.2%EBITDA
$-10.01B-307.7%Free Cash Flow
$3.69B-12.0%EPS (diluted)
$-8.45-439.4%Shares Outstanding (diluted)
1.24B-7.2%Operating Expenses
$3.69BCash & Debt
$3.18BReturn of Capital
$1.38BRevenue by Segment (annual)
$29.44BDividend per Share
$0.82Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $29.44B | $8.51B | $6.84 |
| 2024 | $28.75B | $480.00M | $0.38 |
| 2023 | $27.12B | $5.67B | $4.54 |
| 2022 | $27.28B | $4.59B | $3.66 |
| 2021 | $27.30B | $6.22B | $4.96 |
| 2020 | $24.69B | $123.00M | $0.10 |
| 2019 | $22.45B | $5.39B | $4.24 |
| 2018 | $22.13B | $5.46B | $4.20 |
| 2017 | $26.11B | $4.63B | $3.54 |
| 2016 | $30.39B | $13.50B | $10.08 |
| 2015 | $32.64B | $18.11B | $12.37 |
| 2014 | $24.89B | $12.10B | $7.95 |
| 2013 | $11.20B | $3.08B | $2.01 |
| 2012 | $9.70B | $2.59B | $1.71 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GILD's reported EPS growth of 11.3% a year over 13 years.
- EPS in 5 years
- $11.68
- Implied price
- $210.31
- Return from $144.74
- 7.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $104.56 — -27.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| 1.3% | -9.6% | -5.4% | -1.9% | 1.1% | 3.9% |
| 6.3% | -5.1% | -0.8% | 2.9% | 6.1% | 9.0% |
| 11.3% | -0.6% | 3.9% | 7.8% | 11.1% | 14.1% |
| 16.3% | 3.8% | 8.6% | 12.6% | 16.1% | 19.3% |
| 21.3% | 8.3% | 13.2% | 17.4% | 21.1% | 24.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80+242.86%Social Signal Score
Mentions (46)
- Newszacks.com·3d ago·Positive
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.
View source ↗ - Newsbarrons.com·4d ago·Neutral
More Upside Awaits for Gilead Sciences Stock. Stay Invested. Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
View source ↗ - Newszacks.com·4d ago·Neutral
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newszacks.com·5d ago·Neutral
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.
View source ↗ - News (RSS)seekingalpha·12d ago·Neutral
Gilead: HIV Growth Is Not Enough At The Current Price
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
…l Society, says AHF MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around conc…
View source ↗ - Newszacks.com·18d ago·Neutral
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·19d ago·Neutral
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
View source ↗ - News (RSS)seekingalpha·20d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an “inflection point in value.”
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·21d ago·Neutral
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.
View source ↗ - News (RSS)yahoo·24d ago·Negative
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·25d ago·Positive
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth Gilead Sciences NASDAQ: GILD CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·26d ago·Neutral
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined the company's priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritization and execution.
View source ↗ - Newszacks.com·27d ago·Negative
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.
View source ↗ - News (Marketaux)insidermonkey.com·28d ago·Positive
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market? Gilead Sciences, I[+202 characters]
View source ↗ - News (RSS)fool·30d ago·Neutral
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
View source ↗ - Newsfool.com·30d ago·Positive
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? Gilead is best known for its dominant HIV franchise. But the company has been actively diversifying via acquisitions.
View source ↗ - News247wallst.com·31d ago·Negative
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.
View source ↗ - Newszacks.com·34d ago·Neutral
Can Bixlenvo Unlock New Growth for Gilead's HIV Business? GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
View source ↗ - Newszacks.com·34d ago·Positive
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock? Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - Newszacks.com·34d ago·Neutral
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
View source ↗ - Newszacks.com·38d ago·Neutral
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
View source ↗ - Newsreuters.com·39d ago·Negative
US FDA approves Gilead's once-daily combination pill for HIV treatment The U.S. Food and Drug Administration has approved Gilead Sciences' once daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the company said on Thursday.
View source ↗ - Newscnbc.com·39d ago·Negative
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment regimens. The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a centerpiece of the company's long-term strategy for HIV treatment and prevention.
View source ↗ - Newsbusinesswire.com·39d ago·Negative
… Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people wi…
View source ↗ - Newsfool.com·40d ago·Neutral
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
View source ↗ - Newszacks.com·41d ago·Neutral
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
View source ↗ - Newsbusinesswire.com·43d ago·Neutral
…of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior sy…
View source ↗ - News (Marketaux)finance.yahoo.com·43d ago·Positive
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise? Gilead Sciences, I[+282 characters]
View source ↗ - News (RSS)yahoo·43d ago·Negative
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
View source ↗ - Newsdefenseworld.net·45d ago·Negative
Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD Advisors Capital Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 31,697 shares of the biopharmaceutical company's stock, valued at approximately $4,005,000. Other institutional investors and hedge funds
View source ↗ - News (RSS)seekingalpha·47d ago·Neutral
Gilead rises for the seventh straight session
View source ↗ - Newszacks.com·48d ago·Positive
Is Gilead's Expanding HIV Portfolio a Growth Catalyst? Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
View source ↗ - Newsfool.com·49d ago·Negative
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
View source ↗ - News (RSS)thestreet·49d ago·Negative
Gilead yanks out a thorn in its side in major court ruling A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company's revenue. The decision blocks a group of companies from importing cheaper foreign versions of Gilead's top HIV drug and selling them to American patients. For a company that relies heavily on a ...
View source ↗ - News (RSS)seekingalpha·50d ago·Positive
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
View source ↗ - Newscnbc.com·52d ago·Positive
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to shrink.
View source ↗ - News (RSS)seekingalpha·55d ago·Neutral
SA analyst upgrades/downgrades: INTC, AMD, ANET, GILD
View source ↗ - News (RSS)investing.com·55d ago·Neutral
Gilead Sciences options activity points to institutional conviction on 2026 upside
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade) Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter. On the other hand, Livdelzi, a PPARδ agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.
View source ↗ - News (RSS)wsj·62d ago·Negative
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $2.12 per share
Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-6.75 vs $-7.25beat
- Thu, May 7$2.03 vs $1.91beat
- Tue, Feb 10$1.86 vs $1.81beat
- Thu, Oct 30$2.47 vs $2.13beat
- Thu, Aug 7$2.01 vs $1.96beat
- Thu, Apr 24$1.81 vs $1.78beat
Estimates and results for GILD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GILD officers and directors.
- Bought
- —
- Sold
- $24.4m
0 trades
40 trades
- O'day Daniel Patricksold
- O'day Daniel Patricksold
- Dickinson Andrew Dsold
- Mercier Johannasold
- Mercier Johannasold
- Mercier Johannasold
- O'day Daniel Patricksold
- O'day Daniel Patricksold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Sep 7, 2026 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (817d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (817d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (817d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Jun 22, 2026 (47d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Jun 22, 2026 (47d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 27, 2026 (31d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Jun 19, 2025 (13d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 12, 2025 (29d later)Sell$1,001 - $15,000
- John Boozmansenate · AR · disclosed May 14, 2025 (28d later)Sell$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed May 7, 2025 (2d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (14d later)Buy$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 11, 2025 (35d later)Buy$1,001 - $15,000
- Carol Devine Millerhouse · WV01 · disclosed Apr 11, 2025 (32d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Dec 30, 2024 (6d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.